Kelly K Hunt
@KellyKhunt
Followers
3K
Following
8K
Media
79
Statuses
628
Professor of Surgery at MD Anderson Cancer Center. Devoted to cancer care & research. Tweets are my own.
Houston, TX
Joined October 2014
RT @SocSurgOnc: New episode!. Dr. Olga Kantor, Brigham and Women’s Hospital, and Dr. Taiwo Adesoye, MD Anderson Cancer Center, dive into ke….
0
3
0
RT @HelenMJohnsonMD: Strong presentation by @MDAndersonNews BSO fellow Dr Tori Hunyh @THuynhMD at #ASBrS2025 @ASBrS. #pCR is associated wit….
0
5
0
RT @SocSurgOnc: The Society of Surgical Oncology is pleased to announce the newly installed Officers and Board Members as they officially b….
0
14
0
RT @HelenMJohnsonMD: Congratulations to Drs Tori Hunyh and Ashley Cairns, @MDAndersonNews breast surgical oncology fellows, on their #SSO20….
0
1
0
RT @JenniferPlichta: So thankful 🙏 to have been a member of the inaugural @SocSurgOnc Career Catalyst Program and for my amazing mentor @Ke….
0
7
0
RT @SanjaySReddy: Recently completed our year long @SocSurgOnc #careercatalyst program with 7 amazing mentees! Special 🙏 to my mentors @Dar….
0
4
0
RT @oncodaily: Targeting the Cell Cycle Machinery in Cancer with @kandymarsy and @KellyKhunt - @weldeiry . #FightA….
oncodaily.com
Wafik El-Deiry: Targeting the Cell Cycle Machinery in Cancer with Khandan Keyomarsi and Kelly Hunt / cancer, cell cycle, fight against cancer, Global
0
5
0
RT @kandymarsy: We are pleased to share our latest findings on the molecular mechanisms driving resistance to CDK4/6 inhibitors in HR+/HER2….
0
2
0
Don’t forget to watch the video with Dr. Mamounas! He has so much experience to share! #BRCAbrief @DrSGraff @SocSurgOnc @ASBrS.
Catch this #BRCABrief tonight on @SoMeCME!. 🗣️ Terry Mamounas, MD, MHP, FACS, @DrSGraff, & @KellyKhunt will cover what the future holds in BRCA+ early #breastcancer. 🗓️ Wednesday, February 12, 2025.🕔 5:00 PM EST. Follow along using #BRCABrief
1
0
7
Thanks @DrSGraff #BRCA testing can have implications for individual patient treatment plans and potential for cascade testing to their family members. #BRCAbrief.
@SoMeCME @KellyKhunt Learn more about methods to meet patient needs in #BRCA testing and counseling #BRCAbrief .👉
0
1
3
Know the guidelines. Surgeons and APPs need to be all in for our patients! Surgeons can definitely help with offering germline testing #BRCAbrief @SocSurgOnc @ASBrS @DrSGraff.
mdpi.com
For patients with newly diagnosed breast cancer, information regarding hereditary predisposition can influence treatment decisions. From a surgical standpoint, patients with known germline mutations...
2/ Guidelines support expanded germline testing, but most genetic counselors are distributed across only 10 states. What are the available options❓. 👉 #BRCABrief #BCRA
0
1
6
Check out this educational opportunity to learn more about BRCA+ early breast cancer with Dr. Terry Mamounas @DrSGraff @SocSurgOnc @ASBrS.
Catch this #BRCABrief tonight on @SoMeCME!. 🗣️ Terry Mamounas, MD, MHP, FACS, @DrSGraff, & @KellyKhunt will cover what the future holds in BRCA+ early #breastcancer. 🗓️ Wednesday, February 12, 2025.🕔 5:00 PM EST. Follow along using #BRCABrief
0
7
14
RT @SocSurgOnc: Happy #InternationalDayofWomenandGirlsinScience! Today, we celebrate the incredible women shaping the future of surgical o….
0
3
0
Don’t forget to watch the video w/Dr. Terry Mamounas on how germline testing impacts treatment @DrSGraff #BRCAbrief.
6/ We hope you enjoyed this #BRCAbrief!. Complete the posttest & evaluation here 👉 & claim your 🆓 CME!. 🗓️ See you for our next #breastcancer #BRCA brief w/ Terry Mamounas, MD, @DrSGraff, & @KellyKhunt
0
2
8
Learn more about integrating olaparib in the management of patients with germline BRCA mutations who have early breast cancer
academic.oup.com
This article reviews available data that could help guide treatment decisions for germline BRCA1/2 mutation carriers with high-risk, early-stage breast can
@SoMeCME Adjuvant olaparib significantly improves IDFS, DDFS, and OS in #BRCAbrief @KellyKhunt . Here’s the abstract from #SABCS24 @judygarber5 👉
0
2
9
Agree @DrSGraff and patients with germline #BRCA mutations who have residual disease following neoadjuvant systemic therapy should be considered for adjuvant therapy with a PARP inhibitor. #BRCAbrief.
@SoMeCME @KellyKhunt And importantly, how do you capture all the patients that qualify for testing? Any patient who may be eligible for a PARP inhibitor is eligible for testing—which includes ER+ disease. #BRCAbrief.
0
1
6
Let’s start the conversation. It takes the whole multidisciplinary team to develop the optimal treatment program for our patients @DrSGraff Dr. Terry Mamounas @SocSurgOnc @ASBrS #BRCAbrief #bcsm.
1/ #BRCAbrief #BRCA. Personalizing treatment decisions in early #breastcancer w/ Terry Mamounas, MD, @DrSGraff, & @KellyKhunt. Supported by educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC. CME ℹ️ 📊 What is your.
0
1
6
RT @SocSurgOnc: From the February Issue of @AnnSurgOncol: Significance of Residual Nodal Disease in Clinically Node-Negative #BreastCancer….
0
3
0
When we identify gBRCA mutations in patients it can impact surgical decision-making and adjuvant therapy recommendations. Cascade testing can also be important for family members. #bcsm @DrSGraff.
6/ We hope you enjoyed this #BRCAbrief!. Complete the posttest & evaluation here 👉 & claim your 🆓 CME!. 🗓️ See you for our next #breastcancer #BRCA brief w/ Terry Mamounas, MD, @DrSGraff, & @KellyKhunt
0
3
5
Many consider genetic testing for patients with triple negative breast cancer but those patients with hormone receptor positive breast cancer and HER2+ breast cancer can also harbor pathogenic mutations that may impact their management #BRCA.
0
3
4